PLoS Pathogens (Sep 2019)

HLA-B locus products resist degradation by the human cytomegalovirus immunoevasin US11.

  • Cosima Zimmermann,
  • Daniel Kowalewski,
  • Liane Bauersfeld,
  • Andreas Hildenbrand,
  • Carolin Gerke,
  • Magdalena Schwarzmüller,
  • Vu Thuy Khanh Le-Trilling,
  • Stefan Stevanovic,
  • Hartmut Hengel,
  • Frank Momburg,
  • Anne Halenius

DOI
https://doi.org/10.1371/journal.ppat.1008040
Journal volume & issue
Vol. 15, no. 9
p. e1008040

Abstract

Read online

To escape CD8+ T-cell immunity, human cytomegalovirus (HCMV) US11 redirects MHC-I for rapid ER-associated proteolytic degradation (ERAD). In humans, classical MHC-I molecules are encoded by the highly polymorphic HLA-A, -B and -C gene loci. While HLA-C resists US11 degradation, the specificity for HLA-A and HLA-B products has not been systematically studied. In this study we analyzed the MHC-I peptide ligands in HCMV-infected cells. A US11-dependent loss of HLA-A ligands was observed, but not of HLA-B. We revealed a general ability of HLA-B to assemble with β2m and exit from the ER in the presence of US11. Surprisingly, a low-complexity region between the signal peptide sequence and the Ig-like domain of US11, was necessary to form a stable interaction with assembled MHC-I and, moreover, this region was also responsible for changing the pool of HLA-B ligands. Our data suggest a two-pronged strategy by US11 to escape CD8+ T-cell immunity, firstly, by degrading HLA-A molecules, and secondly, by manipulating the HLA-B ligandome.